Cargando…
Glucocorticoid benefits the ventilatory function of severe/critical COVID-19 patients
Autores principales: | Xiong, Xiaoming, Jiao, Xiaofei, Li, Huayi, Zeng, Shaoqing, Wang, Ya, Gao, Qinglei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673216/ https://www.ncbi.nlm.nih.gov/pubmed/33220384 http://dx.doi.org/10.1016/j.jinf.2020.11.017 |
Ejemplares similares
-
A real‐world study of glucocorticoid treatment in COVID‐19 patients with different disease severities
por: Jiao, Xiaofei, et al.
Publicado: (2020) -
In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension
por: Yuan, Yuan, et al.
Publicado: (2020) -
Immunity‐modulated sex disparity on COVID‐19 prognosis
por: Liu, Dan, et al.
Publicado: (2020) -
CIRPMC: An online model with simplified inflammatory signature to predict the occurrence of critical illness in patients with COVID‐19
por: Gao, Yue, et al.
Publicado: (2020) -
Alteration of serum markers in COVID‐19 and implications on mortality
por: Liu, Dan, et al.
Publicado: (2020)